FINWIRES · TerminalLIVE
FINWIRES
$MRK

$MRK

124 stories mentioning MRKUpdated 16d ago

Every FINWIRES story that references MRK, newest first.

What are analysts saying about MRK?

Recent broker actions mentioned in FINWIRES coverage. Compiled from wire headlines; not investment advice.

What's the latest news on MRK?

Wire

Top Midday Gainers

ZeroStack (ZSTK) said Wednesday it entered a $1 billion crypto contribution agreement that will add nearly 926 million MemeCore tokens to the company and also give MemeCore-linked investors a substantial equity stake in the company.Shares were up roughly 200% as intraday trading volume catapulted to over 20 million from a daily average of more than 18,300.Moderna (MRNA) and Merck (MRK) said a trial of intismeran autogene plus Keytruda met the primary endpoint of recurrence-free survival and a key secondary endpoint of distant metastasis-free survival in people with completely resected stage IIB-IV melanoma.Shares of Moderna rose about 141%, with intraday trading volume at over 148.9 million against a daily average of roughly 6.9 million.SKK Holdings (SKK) said its SKK Works unit secured six new contracts for horizontal directional drilling and utility works in Singapore.Shares increased about 20% as intraday trading volume soared to over 7.5 million from a daily average of roughly 21,400 shares.Price: $5.50, Change: $+3.65, Percent Change: +198.63%

$MRK$MRNA$SKK$ZSTK
Asia Markets

US Equity Indexes Rise as Bond Yields Ease After Treasury Raises Buyback Cap, Trump Pauses Canada Tariffs

US equity indexes rose after midday Wednesday after the Treasury Department said it would increase buybacks of long-dated government debt to at least $4 billion per operation in September from $2 billion, and President Donald Trump paused tariffs on certain Canadian goods in a late Tuesday Truth Social post.The Nasdaq Composite rose 0.2% to 26,343.5, and the S&P 500 gained 0.3% to 7,716.1. The Dow Jones Industrial Average increased 0.2% to 53,456.1. Health and materials led the gainers, while technology and industrials led the decliners.The yield on 30-year Treasuries fell 7 basis points to 5.215%, while the 10-year yield fell 3 basis points to 4.677%.Trump also said the proposed Keystone XL Pipeline, which was canceled in 2021, may be revived. The tariff play comes ahead of negotiations for the US-Mexico-Canada Trade Agreement.Gold futures gained 3% to $4,553.5 per ounce, and silver futures rose 3% to $65.95.In economic news, US crude oil stocks, including those in the Strategic Petroleum Reserve, fell by 900,000 barrels in the week ended Aug. 14, following an increase of 11.3 million barrels in the prior week.Excluding SPR inventories, commercial crude oil stocks rose by 4.4 million barrels compared with a 17.4-million-barrel gain in the week prior, and the 200,000-barrel increase expected in a survey compiled by Bloomberg.The US West Texas Intermediate crude oil contract rose 2.4% to $86.99 per barrel.US mortgage applications fell by 0.4% in the week ended Aug. 14, with an increase in refinancing activity offset by declining home purchase applications, according to the Mortgage Bankers Association."In addition to the economic uncertainty, affordability difficulties have reemerged as a reason for homebuyers to delay purchase decisions given the impact of higher mortgage rates on monthly mortgage payments," said MBA deputy chief economist Joel Kan.In company news, Moderna (MRNA) shares climbed 150%, and Merck (MRK) shares gained 11.5% after the companies said a trial of intismeran autogene combined with Keytruda met the primary endpoint of recurrence-free survival and a key secondary endpoint of distant metastasis-free survival in patients with completely resected stage IIB-IV melanoma.Target (TGT) shares rose 5.8% after the company posted higher-than-expected fiscal Q2 results and boosted its 2026 guidance. The company reported fiscal Q2 adjusted earnings of $4.11 per diluted share, up from $2.05 a year earlier and above FactSet consensus of $2.34. Fiscal Q2 net sales were $26.54 billion, up from $25.21 billion a year ago and above the FactSet consensus of $26.13 billion. For fiscal 2026, the company lifted its adjusted EPS guidance to between $9.90 and $10.90 from $7.50 to $8.50 earlier, compared with FactSet estimates of $8.52.

Dow JonesNasdaq CompositeS&P 500$MRK$MRNA$TGT
Update: Equities Rise Intraday Ahead of Fed Minutes
US Markets

Update: Equities Rise Intraday Ahead of Fed Minutes

(Updates with latest market prices and developments.)US benchmark equity indexes were higher intraday, supported by gains in the healthcare sector amid a big rally in Moderna (MRNA) shares, while traders awaited minutes of the Federal Reserve's last policy meeting.The S&P 500 was up 0.3% at 7,716.7 after midday Wednesday, while the Nasdaq Composite rose 0.2% to 26,341.6. The Dow Jones Industrial Average advanced 0.2% to 53,436.2. The indexes finished Tuesday trading lower for the third consecutive session.Among sectors, healthcare paced the gainers, while industrials led the laggards.Moderna shares were up 142%, the biggest gain on the S&P 500, as a late-stage trial for a skin cancer treatment being developed in partnership with Merck (MRK) yielded positive topline results. Merck jumped 11%, the best performer on the Dow and among the top gainers on the S&P 500.Keysight Technologies (KEYS) was the worst performer on the S&P 500, down 6.3%. Late Tuesday, the electronics test and measurement equipment manufacturer provided a fiscal fourth-quarter earnings outlook above Wall Street's estimates and reported better-than-expected third-quarter results.In other corporate news, Target (TGT) lifted its full-year outlook as tariff refunds helped double the retailer's fiscal second-quarter earnings year over year. Its shares were up 5.8% intraday.TJX (TJX) issued a fiscal third-quarter comparable store sales forecast that fell short of the Street expectations, but raised its full-year earnings outlook. The stock fell 2.9%.The Fed is scheduled to post minutes of its most recent policy meeting at 2 pm ET, which will be assessed for fresh insights on the central bank's monetary policy. At the meeting last month, policymakers left interest rates unchanged in a divided decision, with three regional presidents calling for policy tightening.Markets are currently pricing in a 63% probability that the Fed will keep its benchmark rate steady in September, with the remaining odds in favor of a 25-basis-point hike, according to the CME FedWatch tool.Treasury yields were mixed intraday, with the two-year yield up 1.3 basis points at 4.19% while the 10-year yield fell 4.6 basis points to 4.7%.The Treasury Department said Wednesday that it will boost the size of its government debt repurchases to at least $4 billion per operation from $2 billion, effective Sept. 9. The buyback operation will focus on 10- to 30-year Treasuries.West Texas Intermediate crude oil was up 2.3% at $86.87 a barrel intraday, while Brent rose 1.7% to $92.59.The United Arab Emirates is halting all trade and financial transactions with Iran "until further notice" amid "regional escalations that undermine regional and international peace and security," UAE Foreign Ministry spokeswoman Afra Al Hameli said on X. The UAE is Iran's second-largest commercial partner, according to a CNN report."Oil prices extended gains for a fourth consecutive session on Wednesday as uncertainty over a resolution to the US-Iran conflict continued to support risk premiums," ING Bank said.Spot gold jumped 3.7% to $4,495.25 per troy ounce, while silver climbed 3% to $65.96 per ounce.

Dow JonesNasdaq CompositeS&P 500$KEYS$MRK$MRNA$TGT$TJX
Moderna, Merck Report Positive Phase 3 Trial Results of Melanoma Drug; Moderna Shares Jump Over 100%
US Markets

Moderna, Merck Report Positive Phase 3 Trial Results of Melanoma Drug; Moderna Shares Jump Over 100%

Moderna (MRNA) and Merck (MRK) said Wednesday a late-stage trial of an experimental skin cancer treatment yielded positive topline results, sending the companies' shares higher, with Moderna jumping more than 100%.The phase 3 trial evaluated the safety and efficacy of intismeran in combination with Merck's Keytruda, compared with Keytruda alone, in patients with high-risk resected cutaneous melanoma. The study enrolled 1,137 patients.The combination showed "statistically significant and clinically meaningful improvements" in recurrence-free survival and distant metastasis-free survival in certain melanoma patients who had not undergone prior treatment with systemic therapy, the companies said Wednesday.The trial met its primary endpoint of recurrence-free survival and a key secondary endpoint of distant metastasis-free survival. The results also marked the first positive phase 3 readout for an individualized neoantigen therapy and for an mRNA-based cancer therapy, as well as the first late-stage study to show a "clinically meaningful improvement" over Keytruda alone in the adjuvant setting for patients with resected melanoma, Moderna and Merck said. The companies are jointly developing the treatment.Moderna shares were up 148% in afternoon trade, while Merck jumped 11%."For many years, the idea of creating an mRNA treatment designed specifically for an individual patient's cancer was aspirational. We are now helping turn that vision into a reality," Moderna Chief Executive Stephane Bancel said. "Together with Merck, we have started to demonstrate the transformative potential of this technology to address critical unmet needs in the adjuvant melanoma setting."The trial showed that the safety profiles of intismeran and Keytruda were consistent with previously reported results from the combination, with "no new safety signals" seen, the companies said.In June, data from a phase 2b trial showed that the combination reduced the risk of recurrence or death by 49%, compared with Keytruda alone. That study also demonstrated a 59% reduction in the risk of the disease spreading to other parts of the body or death.The latest trial will continue to evaluate other secondary endpoints, such as overall survival, the companies said Wednesday."These first phase 3 findings for intismeran in combination with Keytruda as adjuvant therapy reinforce the promise of a more personalized approach to cancer treatment," said Merck Research Laboratories President Dean Li. "We believe individualized neoantigen therapies have the potential to redefine how patients with completely resected stage IIB-IV melanoma are treated."Price: $148.10, Change: $+85.14, Percent Change: +135.23%

$MRK$MRNA
Sectors

Sector Update: Healthcare Stocks Gain Wednesday Afternoon

Healthcare stocks were higher Wednesday afternoon, with the NYSE Healthcare Index rising 2.2% and the State Street Health Care Select Sector SPDR ETF (XLV) adding 2.7%.The iShares Biotechnology ETF (IBB) climbed 4.8%.In sector news, President Donald Trump said Wednesday he has nominated Heidi Overton as the US Food and Drug Administration Commissioner. "We need her leadership at the FDA now to ensure that the US remains the WORLD LEADER for Scientific Discovery and CURES," Trump said in a post on Truth Social.In corporate news, Moderna (MRNA) shares surged 146% and Merck (MRK) shares jumped past 11% after the companies said a trial of intismeran autogene plus Keytruda met the primary endpoint of recurrence-free survival and a key secondary endpoint of distant metastasis-free survival in people with completely resected stage IIB-IV melanoma.Sight Sciences (SGHT) shares jumped past 6% after the company said that the US Food and Drug Administration has updated the TearCare System's indication to include improving meibomian gland function in adult patients with evaporative dry eye disease caused by meibomian gland dysfunction.Teva Pharmaceutical Industries (TEVA) shares rose 1.6% after its US affiliate Teva Pharmaceuticals said Wednesday the US Food and Drug Administration has accepted its new drug application for ecopipam to potentially treat children with Tourette syndrome.

$MRK$MRNA$SGHT$TEVA
Asia Markets

Exchange-Traded Funds Higher as US Equities Gain After Midday

Broad Market IndicatorsBroad-market exchange-traded funds IWM and IVV were higher. Actively traded Invesco QQQ Trust (QQQ) gained 0.3%.US equity indexes rose after midday Wednesday as Moderna (MRNA) and Merck (MRK) surged on positive results from a late-stage trial of their melanoma vaccine, and the US Treasury said it would double the buybacks of long-dated government debt.EnergyIShares US Energy ETF (IYE) gained 0.5% and the State Street Energy Select Sector SPDR (XLE) rose about 0.3%.TechnologyThe State Street Technology Select Sector SPDR ETF (XLK) shed 0.5%; iShares US Technology ETF (IYW) eased 0.2% and iShares Expanded Tech Sector ETF (IGM) also declined 0.3%.The State Street SPDR S&P Semiconductor (XSD) shed 1.7%, and iShares Semiconductor (SOXX) was down 1.6%.FinancialThe State Street Financial Select Sector SPDR (XLF) declined 0.1%. Direxion Daily Financial Bull 3X Shares (FAS) advanced 0.4%, and its bearish counterpart, Direxion Daily Financial Bear 3X Shares (FAZ), declined 0.4%.CommoditiesCrude oil rose 2%, and the United States Oil Fund (USO) added 1.5%. Natural gas gained 1.8%, and the United States Natural Gas Fund (UNG) was up 1.4%.Gold on Comex increased 3.1%, and the State Street SPDR Gold Shares (GLD) was up 3.4%. Silver was 3.1% higher, and iShares Silver Trust (SLV) was up 3.6%.ConsumerThe State Street Consumer Staples Select Sector SPDR (XLP) was up 0.9%. The Vanguard Consumer Staples ETF (VDC) added 0.9%, and iShares Dow Jones US Consumer Goods (IYK) rose 0.3%.The State Street Consumer Discretionary Select Sector SPDR (XLY) was up 1.8%. VanEck Retail ETF (RTH) added 1.1%, and the State Street SPDR S&P Retail (XRT) rose 2%.HealthcareThe State Street Health Care Select Sector SPDR (XLV) added 2.6%. iShares US Healthcare (IYH) gained 2.8% and Vanguard Health Care ETF (VHT) was 2.5% higher. IShares Biotechnology ETF (IBB) climbed up 4.6%.IndustrialThe State Street Industrial Select Sector SPDR (XLI) shed 0.5%. Vanguard Industrials Index Fund (VIS) fell 0.5%, and iShares US Industrials (IYJ) was also down 0.2%.CryptocurrencyIn midday activity, bitcoin (BTC-USD) rose 6.4%. Among cryptocurrency ETFs, ProShares Bitcoin ETF (BITO) added 6.4%, ProShares Ether ETF (EETH) was up 9.6%, and ProShares Bitcoin & Ether Market Cap Weight ETF (BETH) was 7.3% higher.

Dow Jones^EEM^EXI^FAS^FAZ^GLD^IBB^IGM^IGV^IPK^IVV^IWMNasdaq Composite^IYE^IYH^IYJ^IYK^IYW^PMR^QQQ^RTH^SOXXS&P 500^SPY^UNG^USO^VDC^VHT^VIS^XLE^XLF^XLI^XLK^XLP^XLV^XRT^XSD$BETH$BITO$EETH$MRK$MRNA
Sectors

Sector Update: Healthcare

Healthcare stocks were higher Wednesday afternoon, with the NYSE Healthcare Index rising 2.2% and the State Street Health Care Select Sector SPDR ETF (XLV) adding 2.7%.The iShares Biotechnology ETF (IBB) climbed 4.8%.In corporate news, Moderna (MRNA) shares surged 133% and Merck (MRK) shares jumped nearly 11% after the companies said a trial of intismeran autogene plus Keytruda met the primary endpoint of recurrence-free survival and a key secondary endpoint of distant metastasis-free survival in people with completely resected stage IIB-IV melanoma.

$MRK$MRNA
Japan

US Equity Indexes Rise as Treasury Yields Ease on Buyback Ramp

US equity indexes rose on Wednesday after the Treasury said it would at least double the size of buybacks of long-dated government debt, driving long-term Treasury yields sharply lower from multi-year highs.The Nasdaq Composite rose 0.5% to 26,438.7, and the S&P 500 gained 0.5% to 7,735. The Dow Jones Industrial Average increased 0.3% to 53,536.9. Health and materials sectors led the gainers, while the industrials and utilities sectors led the decliners.The yield on 30-year Treasuries fell 7.9 basis points to 5.21%, while the 10-year yield fell 4.6 basis points to 4.66%.Gold futures gained 3.1% to $4,556.60 per ounce, and silver futures rose 3.2% to $66.06.In economic news, US crude oil stocks, including the Strategic Petroleum Reserve, fell by 900,000 barrels in the week ended Aug. 14, following an increase of 11.3 million barrels in the week earlier.Excluding SPR inventories, commercial crude oil stocks rose by 4.4 million barrels compared with a 17.4-million-barrel gain in the week prior, and above the 200,000-barrel increase expected in a survey compiled by Bloomberg.The US West Texas Intermediate crude oil contract rose 2.1% to $86.74 per barrel.US Mortgage applications fell by 0.4% in the week ended Aug. 14, with an increase in refinancing activity offset by a decline in home purchase applications, according to Mortgage Bankers Association data released Wednesday.In company news, Moderna (MRNA) shares climbed 128%, and Merck (MRK) shares gained nearly 11% after the companies said a trial of intismeran autogene in combination with Keytruda met the primary endpoint of recurrence-free survival and a key secondary endpoint of distant metastasis-free survival in patients with completely resected stage IIB-IV melanoma.

Dow JonesNasdaq CompositeS&P 500$MRK$MRNA
Wire

Top Midday Stories: Treasury Lifts Buyback Cap on Long-Dated Securities; Moderna, Merck Say Melanoma Vaccine Meets Primary Endpoint in Trial

All three major US stock indexes were up in late-morning trading Wednesday, after the Treasury Department said it was raising the cap on its buyback operations for longer-dated nominal coupon securities to at least $4 billion per operation from $2 billion, effective Sept. 9.In company news, Moderna (MRNA) and Merck (MRK) said Wednesday that a late-stage trial of intismeran autogene in combination with Keytruda met its primary endpoint of recurrence-free survival in patients with completely resected stage IIB-IV melanoma. The vaccine also met a key secondary endpoint of distant metastasis-free survival in patients, the companies said. Moderna shares were up 122.9% around midday, while Merck shares were up 11.1%.Marvell Technology (MRVL) issued a warrant to Alphabet's (GOOG, GOOGL) Google to buy up to a total of 59.0 million shares of its common stock at $206.58 per share as part of an expanded partnership agreement the two companies reached on July 29, Marvell said Wednesday in a regulatory filing. Marvell shares were up 8.2%, while Alphabet's Class C and Class A shares were up 0.1% and 0.2%, respectively.Target (TGT) reported fiscal Q2 adjusted earnings Wednesday of $4.11 per diluted share, up from $2.05 a year earlier and above the FactSet consensus analyst estimate of $2.34. Fiscal Q2 net sales were $26.54 billion, up from $25.21 billion a year ago and above the FactSet consensus of $26.13 billion. For fiscal 2026, the company lifted its adjusted EPS guidance to between $9.90 and $10.90 from $7.50 to $8.50, above the FactSet consensus of $8.52. The company said it expects full-year net sales growth around 5%, up a percentage point from its previous guidance. Target shares were up 5.7%.Nebius Group (NBIS) said Wednesday it plans to offer $4.50 billion of convertible senior notes in a private offering to qualified institutional buyers. The notes will be offered in two series: $2.75 billion aggregate original principal amount of convertible notes due 2030 and $1.75 billion aggregate original principal amount of convertible notes due 2034. Nebius shares were down 9.3%.Price: $141.15, Change: $+78.19, Percent Change: +124.18%

$GOOG$GOOGL$MRK$MRNA$MRVL$NBIS$TGT
Wire

Update: Moderna, Merck Shares Rise as Melanoma Therapy Shows 'Statistically Significant Improvement' in Late-Stage Trial

(Updates to include the stock movement in the headline and the first paragraph.)Moderna (MRNA) shares climbed 98% and Merck (MRK) shares gained 9% in Wednesday trading after the companies said a late-stage trial of intismeran autogene in combination with Keytruda met the primary endpoint of recurrence-free survival and a key secondary endpoint of distant metastasis-free survival in patients with completely resected stage IIB-IV melanoma.The combination demonstrated statistically significant and clinically meaningful improvements in both recurrence-free survival and distant metastasis-free survival compared with Keytruda alone, the companies said.The trial will continue to evaluate other secondary endpoints, such as overall survival, the companies said.Safety profiles of intismeran and Keytruda were consistent with previously reported results, with no new safety signals, the companies said.Price: $145.76, Change: $+10.59, Percent Change: +7.83%

$MRK$MRNA
Sectors

Sector Update: Healthcare Stocks Higher in Wednesday Trading

Healthcare stocks were rising Wednesday, with the State Street Health Care Select Sector SPDR ETF (XLV) up 1.6% and the iShares Biotechnology ETF (IBB) 3.2% higher.Moderna (MRNA) shares surged more than 92%, and Merck (MRK) was up 8% after the companies said that a late-stage trial of intismeran autogene in combination with Keytruda met its primary endpoint of recurrence-free survival as well as a key secondary endpoint of distant metastasis-free survival in patients with completely resected stage IIB-IV melanoma.Ideaya Biosciences (IDYA) stock was 1.3% higher after the company said it has entered into a clinical collaboration with Genentech to evaluate a combination therapy for pancreatic cancer.Sight Sciences (SGHT) shares rose over 3% after the company said that the US Food and Drug Administration has updated the TearCare System's indication to include improving meibomian gland function in adult patients with evaporative dry eye disease caused by meibomian gland dysfunction.

$IBB$IDYA$MRK$MRNA$SGHT$XLV
Sectors

Sector Update: Healthcare

Healthcare stocks were rising premarket Wednesday, with the State Street Health Care Select Sector SPDR ETF (XLV) up 1.6% and the iShares Biotechnology ETF (IBB) 3.2% higher.Merck (MRK) and Moderna (MRNA) said a late-stage trial of intismeran autogene in combination with Keytruda met its primary endpoint of recurrence-free survival as well as a key secondary endpoint of distant metastasis-free survival in patients with completely resected stage IIB-IV melanoma. Merck shares were up more than 7% and Moderna stock was rising past 94% pre-bell.

$MRK$MRNA
Asia Markets

Update: US Equity Futures Mostly Flat Pre-Bell as Traders Await Fed Policy Meeting Minutes

(Updates with economic data, recent oil price movement, world markets' overview and corporate stock movements.)US equity futures were mostly flat pre-bell Wednesday as traders awaited the Federal Reserve's policy-setting meeting minutes for further insights on the central bank's rate outlook.Dow Jones Industrial Average futures were 0.2% higher, S&P 500 futures were up 0.1%, and Nasdaq futures were 0.1% lower.The minutes of the Federal Reserve meeting held July 28-29 are scheduled to be released 2 pm ET.President Donald Trump said late Tuesday that the US is not in any current or scheduled talks with Iran. In a post on Truth Social, Trump also reiterated that the Strait of Hormuz is "open and operating," with all mines having been removed or detonated.The UAE has halted trade with Iran after accusing Iran of firing two ballistics missiles towards its territory, which fell into the sea. Iran has denied the allegations, according to multiple reports.Traders digested the latest round of earnings, with Analog Devices (ADI) reporting higher fiscal Q3 adjusted earnings and revenue.Oil prices were lower, with front-month global benchmark North Sea Brent crude down 0.2% at $90.84 per barrel and US West Texas Intermediate crude 0.3% lower at $83.84 per barrel.The Atlanta Fed Business Inflation Expectations survey for August is expected at 10 am ET.In other world markets, Japan's Nikkei closed 3.2% lower, Hong Kong's Hang Seng ended 0.1% higher, and China's Shanghai Composite finished 2.4% lower. Meanwhile, the UK's FTSE 100 was down 0.1%, and Germany's DAX index was 0.2% lower in Europe's early afternoon session.In equities, Merck (MRK) and Moderna (MRNA) shares rose 6.8% and 93%, respectively, after the two companies said that a late-stage trial of intismeran autogene in combination with Keytruda met its primary endpoint of recurrence-free survival, as well as a key secondary endpoint of distant metastasis-free survival, in patients with completely resected stage IIB-IV melanoma. SK Hynix (SKHY) stock was up 5.9%% after the company said it will buy back and cancel 40 trillion South Korean won ($28.69 billion) of treasury shares as part of efforts to boost shareholder returns.On the losing side, Lowe's (LOW) shares fell 1.3% after the company reported fiscal Q2 net sales that fell short of analysts' consensus. TJX Companies (TJX) stock was down 4.3% after the company issued lower-than-expected fiscal Q3 diluted EPS guidance. Nebius Group (NBIS) shares dropped 4.9% after the company said it intends to offer $4.5 billion of convertible senior notes in a private offering to qualified institutional buyers.

Dow JonesNasdaq CompositeS&P 500$ADI$LOW$MRK$MRNA$NBIS$SKHY$TJX
Insider Trading

Merck & Co. Insider Sold Shares Worth $1,350,000, According to a Recent SEC Filing

Chirfi Guindo, Executive Vice President, Strategic Access, Policy, & Communications, on August 13, 2026, sold 10,000 shares in Merck & Co. (MRK) for $1,350,000. Following the Form 4 filing with the SEC, Guindo has control over a total of 36,613 common shares of the company, with 36,613 shares held directly.SEC Filing:https://www.sec.gov/Archives/edgar/data/310158/000031015826000223/xslF345X05/form4.xml

$MRK
Insider Trading

Merck & Co. Insider Sold Shares Worth $10,718,495, According to a Recent SEC Filing

Jennifer Zachary, Executive Vice President, General Counsel, on August 12, 2026, sold 80,315 shares in Merck & Co. (MRK) for $10,718,495. Following the Form 4 filing with the SEC, Zachary has control over a total of 45,509 common shares of the company, with 45,509 shares held directly.SEC Filing:https://www.sec.gov/Archives/edgar/data/310158/000031015826000221/xslF345X05/form4.xml

$MRK
Insider Trading

Merck & Co. Insider Sold Shares Worth $5,942,369, According to a Recent SEC Filing

Richard R. DeLuca, Executive Vice President & President, Merck Animal Health, on August 10, 2026, sold 45,320 shares in Merck & Co. (MRK) for $5,942,369. Following the Form 4 filing with the SEC, DeLuca has control over a total of 110,167 common shares of the company, with 110,167 shares held directly.SEC Filing:https://www.sec.gov/Archives/edgar/data/310158/000031015826000219/xslF345X05/form4.xml

$MRK
Sectors

Sector Update: Healthcare Stocks Advance Late Afternoon

Healthcare stocks were higher late Wednesday afternoon, with the NYSE Healthcare Index up 0.2% and the State Street Health Care Select Sector SPDR ETF (XLV) adding 0.3%.The iShares Biotechnology ETF (IBB) rose 0.5%.In corporate news, Merck (MRK) shares rose 2.4% after Daiwa upgraded the stock to outperform from neutral and raised its price target to $143 per share from $120.Cencora (COR) said that certain Walgreens volume that was being serviced by the company, separate from the prime vendor agreement, has started moving outside the company from July 1. Meanwhile, Cencora said its prime vendor agreement remains unchanged and accounts for the majority of its business with Walgreens. Cencora shares fell past 5%.Legend Biotech (LEGN) could see pressures from competition and recent leadership change, potentially weighing on Carvykti myeloma therapy strategy, Oppenheimer said. It downgraded Legend to perform from outperform. Shares fell 5.2%.Definium Therapeutics (DFTX) shares rose 5% after the firm said its phase 3 trial of DT120 orally disintegrating tablets in adults with generalized anxiety disorder met its primary endpoint.

$COR$DFTX$LEGN$MRK
Sectors

Sector Update: Healthcare

Healthcare stocks were higher late Wednesday afternoon, with the NYSE Healthcare Index up 0.1% and the State Street Health Care Select Sector SPDR ETF (XLV) adding 0.3%.The iShares Biotechnology ETF (IBB) rose 0.5%.In corporate news, Merck (MRK) shares rose 2.6% after Daiwa upgraded the stock to outperform from neutral and raised its price target to $143 per share from $120.

$MRK
Wire

Merck Shares Rise After Daiwa Upgrade

Merck (MRK) shares rose over 2.5% in Wednesday trading after Daiwa upgraded the stock to outperform from neutral and raised its price target to $143 per share from $120.Trading volume stood at about 5.4 million shares, compared with a daily average of about 10.2 million.Price: $133.60, Change: $+3.18, Percent Change: +2.44%

$MRK
Research

Daiwa Upgrades Merck & Co. to Outperform From Neutral, Adjusts PT to $143 From $120

Merck & Co. (MRK) has an average rating of overweight and mean price target of $137.56, according to analysts polled by FactSet.

$MRK

Showing 21-40 of 124

Track with the FINWIRES app suite

FolioX
FolioX
Track MRK in your portfolio
WheelAI
WheelAI
Analyze MRK options with the wheel strategy
StockInsider
StockInsider
See market sentiment on MRK